title: Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
abstract: Topical corticosteroids and keratolytics are both used widely in the management of patients with psoriasis. A combination of the two types of agents may provide enhanced relief. The purpose of this study was to compare the efficacy and safety of the combination ointment mometasone furoate 0.1% plus salicylic acid 5% with that of mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis vulgaris. A total of 408 patients were enrolled in this controlled, randomized, double-masked, parallel-group, multicenter comparison. Patients applied either mometasone furoate-salicylic acid ointment or mometasone furoate ointment alone to target lesions twice daily for 21 days. Severity of erythema, induration, and scaling were scored at baseline and at days 4, 8, 15, and 22. An evaluation of overall change in disease status of all treated lesions was performed at each follow-up visit. Adverse events were also monitored and scored, including signs of skin atrophy. Beginning on day 8, the combination of mometasone furoate-salicylic acid was significantly more effective than mometasone furoate alone, as indicated by the mean percentage of improvement in total disease scores, mean total disease sign scores, and the individual score for scaling. Similarly, the combination was more effective beginning on day 15, as indicated by the global evaluation of overall clinical response and individual scores for erythema and induration. Both treatments were well tolerated. Mometasone furoate-salicylic acid ointment provides more effective treatment of moderate-to-severe psoriasis than does mometasone furoate ointment alone and is safe and well tolerated.
authors.affiliation: Psoriasis Treatment Center, University of California, San Francisco School of Medicine, USA.
authors.forename: J
authors.initials: J
authors.lastname: Koo
authors.forename: C A
authors.initials: CA
authors.lastname: Cuffie
authors.forename: D J
authors.initials: DJ
authors.lastname: Tanner
authors.forename: R
authors.initials: R
authors.lastname: Bressinck
authors.forename: R C
authors.initials: RC
authors.lastname: Cornell
authors.forename: R L
authors.initials: RL
authors.lastname: DeVillez
authors.forename: L
authors.initials: L
authors.lastname: Edwards
authors.forename: D L
authors.initials: DL
authors.lastname: Breneman
authors.forename: D J
authors.initials: DJ
authors.lastname: Piacquadio
authors.forename: C A
authors.initials: CA
authors.lastname: Guzzo
authors.forename: E W
authors.initials: EW
authors.lastname: Monroe
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D004890:Erythema / Q000188:drug therapy / Q000473:pathology; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012459:Salicylates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020156:Salicylic Acid
chemical_list: D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D007641:Keratolytic Agents; D011244:Pregnadienediols; D012459:Salicylates; D000068656:Mometasone Furoate; D020156:Salicylic Acid